The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19).

@inproceedings{CerqueiraSilva2021TheEO,
  title={The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19).},
  author={Thiago Cerqueira-Silva and Valterlinda Alves de Oliveira and J{\'u}lia Moreira Pescarini and Jorge Bertoldo J{\'u}nior and Telma M. Santos Machado and Raquel Ortiz and Giana Berleze Penna and Maria Yury Travassos Ichihara and J. Venancio de Barros and Viviane S. Boaventura and Maur{\'i}cio Lima Barreto and Guilherme Loureiro Werneck and M. Barral-Netto},
  booktitle={medRxiv},
  year={2021}
}
Background High rates of virus transmission and the presence of variants of concern can affect vaccine effectiveness (VE). Both conditions occur in low-income countries, which primarily use viral vector or inactivated virus vaccine technologies. However, few VE analyses have been conducted in such countries, and most lack the power to evaluate effectiveness in subgroups, such as the elderly. Methods The present retrospective cohort study evaluated the effectiveness of Vaxzevria and CoronaVac… 

Profile of Brazilian inpatients with COVID-19 vaccine breakthrough infection and risk factors for unfavorable outcome

TLDR
The epidemiological and clinical profile of individuals more likely to become infected by SARS-CoV-2 after the fully vaccination schedule is characterized to profile priority groups to receive a booster dose in situations of vaccine doses shortage as well as for maintenance of personal protective care.

Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It

TLDR
This review looks into the efficacy and safety of COVID-19 vaccination booster to guide clinical decisions on when and who to receive booster vaccination.

Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil

TLDR
A high prevalence of anti- SARS-CoV-2 total antibodies and anti-SARS- CoV- 2 neutralizing antibodies in individuals who received both doses of the Coronavac vaccine is revealed, suggesting a lower effectiveness of the humoral immune response among those older than 60 years of age, which might be associated with senescence of the immune system.

Covid-19: virology, variants, and vaccines

TLDR
The genetics, structure, and transmission methods of SARS-CoV-2 and its variants are discussed, highlighting how mutations provide enhanced abilities to spread and inflict disease.

References

SHOWING 1-10 OF 29 REFERENCES

Effectiveness of the ChAdOx1 vaccine in the elderly during SARS-CoV-2 Gamma variant transmission in Brazil

TLDR
Completion of the ChAdOx1 vaccine schedule afforded significantly increased protection over a single dose against mild and severe Covid-19 outcomes in elderly individuals during widespread Gamma variant transmission.

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

TLDR
The results suggest that the inactivated SARS-CoV-2 vaccine effectively prevented Covid-19, including severe disease and death, a finding that is consistent with results of phase 2 trials of the vaccine.

Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study

TLDR
CoronaVac was 42% effective in the real-world setting of extensive P.1 transmission, but significant protection was not observed until completion of the two-dose regimen, underscore the need to maintain non-pharmaceutical interventions when mass vaccination with CoronaVac is used as part of an epidemic response.

The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data

  • G. ChodickL. Tene K. Muhsen
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2021
TLDR
The effectiveness of the BNT162b2 vaccine in preventing SARS-CoV-2 infection and COVID-19-related hospitalization and mortality is comparable to the one reported in the phase III clinical trial.

The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States

  • S. MoghadasT. Vilches A. Galvani
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2021
TLDR
It is shown that vaccination can have a substantial impact on mitigating COVID-19 outbreaks, even with limited protection against infection, and continued compliance with nonpharmaceutical interventions is essential to achieve this impact.

COVID-19 dynamics after a national immunization program in Israel.

TLDR
A larger and earlier decrease in COVID-19 cases and hospitalization was observed in individuals older than 60 years, followed by younger age groups, by the order of vaccination prioritization, which was not observed in the previous lockdown and was more pronounced in early-vaccinated cities.

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

TLDR
Vaccination with either one dose of BNT162b2 or ChAdOx1-S was associated with a significant reduction in symptomatic covid-19 in older adults, and with further protection against severe disease.

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

TLDR
Only modest differences in vaccine effectiveness were noted with the delta variant as compared with the alpha variant after the receipt of two vaccine doses, which would support efforts to maximize vaccine uptake with two doses among vulnerable populations.